Dernières nouvelles pour Lavras Gold (OTC:LGCFF) Stock

Lavras Gold Corp is a exploration company engaged in the exploration and development of the Lavras do Sul gold project located in the state of Rio Grande do Sul, Brazil. The Lavras do Sul gold project is an advanced exploration stage property that is approximately 190 square km in size and comprised of more than 23 prospects centered on historic gold workings. The Company's Current projects include Butia Gold Prospect and the LDS project in Brazil.

Lavras Gold Corp

Cryptocurrency markets are trading higher on Tuesday, with Bitcoin reclaiming $91,000 on the back of the <a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44917155/xrp-leads-ethereum-bleeds-as-crypto-investment-products-see-6-million-in-inflows">strongest institutional ETF inflows</a> since January.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$91,549.61</td>
<td>+5.4%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$1,704.37</td>
<td>+8.5%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$144.88</td>
<td>+7%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.16&nbsp;</td>
<td>+4.3%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1723</td>
<td>+9.8%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001325</td>
<td>+7.4%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 80.2% and daily active addresses growing by 19.3%. Transactions greater than $100,000 are up from 5,571 to 8,839 in a single day. Exchanges netflows are down by 661.9%.</li>
<li>Coinglass data reports 108,998 traders were liquidated in the past 24 hours with the total liquidations at $348.20 million.</li>
<li>Glassnode data <a href="https://x.com/glassnode/status/1914689187736940885">shows</a> Bitcoin open interest increased from $28.5 billion to $30.7 billion over the past 24 hours.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44919277/xrp-solana-dogecoin-among-72-crypto-related-etfs-awaiting-sec-approval">XRP, Solana, Dogecoin Among 72 Crypto-Related ETFs Awaiting SEC Approval,</a></li>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44926052/bitcoin-reclaims-90000-is-digital-gold-heading-to-100000-next">Bitcoin Reclaims $90,000: Is &#8216;Digital Gold&#8217; Heading To $100,000 Next?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44917155/xrp-leads-ethereum-bleeds-as-crypto-investment-products-see-6-million-in-inflows">XRP Leads, Ethereum Bleeds As Crypto Investment Products See $6 Million In Inflows</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44907123/ripple-coinbase-solana-among-crypto-firms-contributing-over-12m-to-trumps-inauguration-fund">Ripple, Coinbase, Solana Among Crypto Firms Contributing Over $12M To Trump&#8217;s Inauguration Fund</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Fartcoin (CRYPTO: FARTCOIN)</td>
<td>$1.07</td>
<td>+23.2%</td>
</tr>
<tr>
<td>Curve DAO Token (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/crv/usd">CRV</a>) </td>
<td>$0.6896</td>
<td>+18.5%</td>
</tr>
<tr>
<td>Immutable (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">IMX</a>)</td>
<td>$0.5565</td>
<td>+18%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader ElonMoney warns that if Bitcoin fails to hold above $91,200 and slips below the 90-day Volume Weighted Average Price (VWAP), a drop toward the 7-day VWAP near $85,500 is likely.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> can't hold above 91,200 and drops back below the 90D VWAP, we're heading back down to test support at the 7D VWAP around 85,500. <a href="https://t.co/r5e6031tRI">pic.twitter.com/r5e6031tRI</a>
&mdash; elonmoney.hl (@0xelonmoney) <a href="https://twitter.com/0xelonmoney/status/1914740718658105821?ref_src=twsrc%5Etfw">April 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto Chase <a href="https://x.com/Crypto_Chase/status/1914738989938221233">identifies</a> $93,500 as a potential distribution zone, noting that the recent sharp rally lacked liquidity sweeps or meaningful retests. 
He remains cautious, flagging the risk of a sudden reversal pointing out that up-only moves often precede down-only corrections, a pattern he's seen play out frequently in past cycles.
Analyst Benjamin Cowen <a href="https://x.com/intocryptoverse/status/1914728548243529792">highlighted</a> a classic Bitcoin pattern playing out around key moving average crosses: first a dump into the cross, followed by a countertrend rally once it completes. 
This familiar setup often serves as a shakeout before a short-term bounce trap late participant.
On-chain insights from CryptoQuant reveal that spot demand for Bitcoin continues to weaken, despite slowing its decline. 
The firm notes that demand momentum is now at its most negative level since October 2024, signaling underlying fragility. 
Without a turnaround in both demand and momentum, a sustained rally remains unlikely.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitcoin spot demand is still falling, but not as fast. Demand momentum just hit its most negative level since Oct '24. Until both recover, sustained upside remains unlikely. <a href="https://t.co/qYx6pryfHC">pic.twitter.com/qYx6pryfHC</a>
&mdash; CryptoQuant.com (@cryptoquant_com) <a href="https://twitter.com/cryptoquant_com/status/1914747578173768134?ref_src=twsrc%5Etfw">April 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44928800/bitcoin-is-dependent-on-the-us-not-a-non-dollar-asset-peter-schiff-says">Bitcoin Is Dependent On The US, Not A &#8216;Non-Dollar Asset,&#8217; Peter Schiff Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$CRV

$DOGE

$ETH

$IMX

$SHIB

$SOL

$XRP

Bitcoin Reclaims $91,000, Ethereum, XRP, Dogecoin Ride The Rally – 'BTC Doing What It Always Does'

Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) shares are rallying Tuesday, nearing all-time highs on continued momentum from strong earnings late last week. Here&#8217;s a look at <a href="https://www.benzinga.com/markets/equities/25/04/44919712/netflix-shares-up-1-6-after-key-signal-even-as-s-p-500-drops-2-4">what&#8217;s going on</a>.
What To Know: Netflix stock has been on a tear this week as investors flock to the name as a <a href="https://www.benzinga.com/trading-ideas/25/04/44909012/how-to-trade-the-one-tariff-proof-tech-stock">safe haven</a> amid tariff uncertainty. Netflix is largely insulated from global tariffs as the company sells streaming subscriptions as opposed to physical goods, and strong earnings from last week appears to have sparked investor confidence. 
Netflix reported first-quarter revenue of $10.54 billion, beating analyst estimates of $10.52 billion. The company reported first-quarter adjusted earnings of $6.61 per share, beating estimates of $5.74 per share, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Total revenue was up 13% year-over-year, driven by membership growth and higher pricing. The streaming giant said results came in above company expectations due to higher-than-forecasted subscription and advertising revenue.
Netflix guided for 15% revenue growth in the second quarter, highlighting continued strong trends in memberships and advertising revenue. The company also forecasted second-quarter earnings of $7.03 per share versus estimates of $6.27 per share.
"We remain optimistic about our 2025 slate with a lineup that includes returning favorites, series finales, new discoveries and unexpected surprises designed to thrill our members," the company said last week. 
Check This Out: <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44930495/wall-street-rebounds-ahead-of-tesla-earnings-dow-adds-1000-points-bitcoin-hits-91000-whats-driving-markets-tuesday">Wall Street Rebounds Ahead Of Tesla Earnings, Dow Adds 1,000 Points, Bitcoin Hits $91,000: What&#8217;s Driving Markets Tuesday?</a>
Following the print, several analysts <a href="https://www.benzinga.com/general/entertainment/25/04/44905838/netflix-playing-offense-while-stock-plays-defense-6-analysts-on-q1-results-advertising-growth-ahead">raised price targets</a> on the streaming stock, ranging from $1,070 to $1,514 per share. 
JPMorgan analysts flagged Netflix as a defensive play for investors, but also noted that the company is &#8220;playing offense.&#8221; The analyst firm believes Netflix will continue to be a key beneficiary of the ongoing disruption of linear TV. 
Several analysts acknowledged Netflix&#8217;s limited exposure to tariffs, suggesting minimal impacts from macroeconomic uncertainty. Many firms also pointed to strong subscriber growth trends and the ability for the company to raise prices and drive stronger revenue growth through its ad-tier plan. 
&#8220;Mgmt confirmed they are not seeing a slowdown or pullback in ad spend given recent macro uncertainty,&#8221; Macquarie analyst Ross Compton said. 
<a href="http://benzinga.com/quote/nflx">Netflix shares</a> reached all-time highs of $1,064.50 in February. The stock is up about 8% over the past few trading sessions and is now within striking distance of the February highs. 
Netflix shares were up 4.8% at $1,035.26 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/04/44905838/netflix-playing-offense-while-stock-plays-defense-6-analysts-on-q1-results-advertising-growth-ahead">Netflix &#8216;Playing Offense&#8217; While Stock Plays Defense: 6 Analysts On Q1 Results, Advertising Growth Ahead</a></li>
</ul>
Photo: FP Creative Stock/Shutterstock.

Analyst Color

Price Target

Movers

NFLX

Netflix Stock Nears All-Time High: What's Going On?

Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced on Tuesday that it will invest $50 billion in the U.S. over <a href="https://www.benzinga.com/topic/pharmaceuticals">the next five years.</a>
These investments further strengthen Roche's already significant U.S. footprint, which includes 13 manufacturing and 15 R&amp;D sites across the Pharmaceutical and Diagnostics Divisions.
The investment is expected to <a href="https://www.roche.com/media/releases/med-cor-2025-04-22" target="_blank" rel="noreferrer noopener">create</a> over 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 jobs at new and expanded facilities.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
As part of this investment, Roche will increase its footprint of more than 25,000 employees in 24 sites across eight U.S. states. The investment will include: 
<ul>
<li>Expanded and upgraded US manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon, and California.</li>
<li>Gene therapy manufacturing facility in Pennsylvania.</li>
<li>A new 900,000-square-foot manufacturing center to support Roche's expanding portfolio of <a href="https://www.benzinga.com/general/biotech/25/04/44791986/whats-going-on-with-viking-therapeutics-structure-therapeutics-stock-on-monday" target="_blank" rel="noreferrer noopener">next-generation weight loss medicines</a>. The company says the location will be announced.</li>
<li>A new manufacturing facility for continuous glucose monitoring in Indiana.</li>
<li>A new R&amp;D center in Massachusetts for conducting artificial intelligence research and as a hub for new cardiovascular, renal, and metabolism R&amp;D efforts.</li>
<li>Significant expansion and upgrading of existing pharmaceuticals and diagnostics R&amp;D centers in Arizona, Indiana, and California.</li>
</ul>
Once all new and expanded manufacturing capacity comes online, Roche will export more medicines from the U.S. than it imports. The company says its diagnostics division already has an export surplus from the U.S. to other countries.
Earlier this month, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertainties" target="_blank" rel="noreferrer noopener">over the next five years</a>.
The move is part of a broader strategy to ensure that all key Novartis medicines for U.S. patients are produced domestically.
Earlier this year, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced its plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>, while Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) plans to double its U.S. drug manufacturing spending from $23 billion to <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">$50 billion within five years</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/25/04/44929060/boeing-finalizes-10-55-billion-deal-to-divest-jeppesen-and-foreflight-assets" target="_blank" rel="noreferrer noopener">Boeing Finalizes $10.55 Billion Deal To Divest Jeppesen And ForeFlight Assets</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Biotech

Large Cap

Health Care

General

RHHBY

Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs

On Tuesday, Sapiens International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) disclosed its plan to acquire Candela for an aggregate <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44915217/sapiens-acquires-candela-to-expand-its-footprint-in-apac-and-enhance-its-life-product-portfolio" rel="noreferrer noopener">cash consideration of&nbsp;$22 million</a>.
Candela offers an end-to-end insurance automation platform along with digital services and solutions in the APAC region.
The acquisition is intended to strengthen Sapiens' life insurance offerings and broaden its footprint across Asia-Pacific.
The deal is anticipated to close in the second quarter of 2025, pending regulatory approvals and closing conditions.
Candela's offerings complement Sapiens' Insurance Platform and Life Policy Administration Systems.
By integrating Candela's strengths in Business Process Modelling (BPM) and Case Management, Sapiens plans to enhance its life insurance solutions.
The acquisition will also allow for the integration of standardized workflows across third-party legacy systems, delivering a more streamlined and consistent experience for agents, customers, and administrators.
Roni Al-Dor, CEO and President at Sapiens, said, "We will continue to support Candela's customers and products, increasing value across the entire insurance lifecycle and supporting insurers' digital transformations with a comprehensive product proposition and a diverse range of service capabilities."
Amitabh Poddar, Business Head at Candela, added, "Integrating our intelligent automation solutions into Sapiens' leading insurance software platform will enhance our capabilities and provide even greater value to our customers."
Notably, Candela reported non-GAAP revenues of $8 million for the full year 2024. The transaction is expected to be accretive to Sapiens' profitability <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">beginning in the fourth quarter of 2025</a>.
The deal is expected in the second quarter of 2025 and Candela will operate as a wholly owned subsidiary of Sapiens.
The company disclosed the first quarter of<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener"> 2025 results on May 8, 2025</a>.
As of December 31, cash and cash <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43775499/sapiens-reports-fourth-quarter-2024-financial-results" rel="noreferrer noopener">equivalent stood at $163.7 million</a>.
Investors can gain exposure to the stock via ARK Israel Innovative Technology ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IZRL#BATS">IZRL</a>).
Price Action: SPNS shares are up 3.30% at $26.28 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44911125/dan-loebs-bet-on-taiwan-semiconductor-looks-strong-as-q1-results-top-expectations" target="_blank" rel="noreferrer noopener">Dan Loeb's Bet On Taiwan Semiconductor Looks Strong As Q1 Results Top Expectations</a></li>
</ul>
Photo via Shutterstock

Equities

Small Cap

IZRL

SPNS

Sapiens Taps APAC Growth With $22 Million Candela Acquisition

WIIM

Shares of retail and consumer discretionary stocks are trading higher following US Treasury Secretary Scott Bessent's reported remarks about trade de-escalation with China. De-escalation with China could reduce supply chain uncertainty and boost consumer sentiment.

Cantor Fitzgerald initiated coverage on Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Monday, citing orforglipron data, which strengthens <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">the case for obesity dominance</a>.
Last week, the U.S. drug giant reported topline Phase 3 results from the ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with <a href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" target="_blank" rel="noreferrer noopener">diet and exercise alone</a>.
In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C (blood sugar) reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential" rel="noreferrer noopener">using the efficacy estimand</a>.
After a choppy second half of 2024, &#8220;Lilly is off to a solid start in &#8217;25,&#8221; Cantor analyst Carter Gould writes. The company reported positive orforglipron ACHIEVE-1 data and improved underlying GLP-1 commercial metrics. 
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44907170/upcoming-pfizer-earnings-call-might-be-focused-on-tariffs-policy-risks-and-obesity-pipeline" rel="noreferrer noopener">Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline</a>
&#8220;&#8230;We view the ACHIEVE-1 data as meaningfully de-risking a 13-16% weight loss profile, and if safety/tolerability holds up, it should leave LLY well-positioned to take share from semaglutide and further grow the market with an oral approach,&#8221; analyst Gould adds.
Cantor writes that Eli Lilly could have an over 85% share of the obesity market by 2029-2030E when the next wave of entrants hits. Cantor initiated with an Overweight rating and a <a target="_blank" href="https://www.benzinga.com/quote/LLY/analyst-ratings" rel="noreferrer noopener">price target of $975</a>.
Eli Lilly&#8217;s first-quarter earnings are in the front row for investors.
The company is scheduled to release the financial performance on 1 May. Analysts expect $4.79 per share earnings with <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $12.93 billion</a>.
Cantor expects modest beats across Mounjaro/Zepbound and that the company will likely reaffirm the FY25 topline guide ($59-61 billion) as a raise is more likely after the second quarter of 2025.
In March, the company announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in India, which is expected to have the second-largest population of overweight or&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44824190/eli-lillys-mounjaro-launch-triggers-weight-loss-craze-in-india-novo-nordisk-seeks-to-move-up-wegovy-launch" rel="noreferrer noopener">obese people by 2050</a>.
Rival&nbsp;Novo Nordisk A/S&#8217;&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) is feeling the pressure as it tries to move up the launch of Wegovy in India to better compete with Lilly.
BofA Securities has also made minor changes to its model for Eli Lilly ahead of Q1 earnings.
BofA analyst Tim Anderson writes that IQVIA recently began including Lilly Direct vials in its TRx (total prescription) data. As for pricing, Eli Lilly expects an overall price decline by the mid-to-high single digits in 2025. While this isn&#8217;t specific to any product, the company suggests that falling prices for its obesity drugs will likely be a major factor.
For 2025/2026, revenues are changed by +1%/+0.4%, and EPS estimates change by +1.9%/-0.7%. No substantial changes to Mounjaro/Zepbound forecasts.
BofA reiterates the Buy rating with a price target of $1,000. &#8220;We continue to like LLY, not &#8220;expensive&#8221; on a PE-to-growth basis, by our math.&#8221;
Price Action: LLY stock is up 0.59% at $822.84 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/04/44928828/devon-energy-unveils-1-billion-annual-optimization-plan-targets-efficiency-gains-by-2026" target="_blank" rel="noreferrer noopener">Devon Energy Unveils $1 Billion Annual Optimization Plan, Targets Efficiency Gains By 2026</a></li>
</ul>
Image: Shutterstock

Initiation

Analyst Ratings

Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence

On 4/20, while most were lighting up, Snoop Dogg dropped a trip—visually speaking.
Directed by Dave Meyers and produced by Psyop in collaboration with Temple Caché, the music video for &#8220;Last Dance with Mary Jane&#8220;—Snoop's cannabis-laced reimagining of the Tom Petty classic—takes viewers on a mind-bending ride through the rapper's life, inner cities and stoner dreams. The track, from Snoop's &#8220;Missionary&#8221; album, released last year via Death Row, Aftermath and Interscope, features Jelly Roll, cameos by B-Real, Method Man, Redman, Wiz Khalifa and even visual nods to Bob Marley, Tupac and Tom Petty himself.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Last Dance with Mary Jane ft. Tom Petty &amp; Jelly Roll (Official Music Video)" width="500" height="281" src="https://www.youtube.com/embed/rseqmSGH7xk?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
This isn't your typical hip-hop video; it's a genre-smashing blend of handcrafted animation and generative AI, layered across a semi-autobiographical storyline about Snoop's lifelong relationship with cannabis and the justice issues it invokes.
"Being able to partner with Dre, Snoop and Dave to create a visual style that hasn't been done is exactly the type of project we live for," said Joe Maggiore of Psyop.
The visuals? Insane. Think 2D, 3D, collage, motion design and surreal AI landscapes. But it's not AI doing the storytelling—every frame was touched by human hands, ensuring emotional nuance and a narrative throughline. "Storytelling requires nuance," said Psyop's Andrew Linsk, explaining why AI alone couldn't carry the vision.
The end result is both a love letter to cannabis and a statement on America—its cities, its culture, its contradictions.
<h2 class="wp-block-heading">Meanwhile… Jet Black Roses Go Full Funkadelic</h2>
If Snoop's video is a lucid dream, Jet Black Roses' new single is a fever-drenched backyard boogie. Its latest track, &#8220;Psychoboogie Hoochiecoo,&#8221; arrives with a brain-melting video by Steffan Heil (of Adult Swim fame) and production by Greg Archilla (Neil Young, Collective Soul, Matchbox Twenty).
No AI. No autotune. Just brass, groove and sweat.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="PsychoBoogieHoochieCoo (Official Music Video)" width="500" height="281" src="https://www.youtube.com/embed/DlQuGfovDEg?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
MusicRow nailed it: "Funky, horn-punctuated Southern rock with some built-in grease."
The band describes itself as the &#8220;Coolest Dad Rock Band in America,&#8221; but that barely scratches it. Picture the swagger of Little Feat, the freak of Funkadelic and the slink of The Meters—wrapped in Jet Black Roses' Louisiana-born harmonies and storytelling.
It&#8217;s shared stages with Styx, Sammy Hagar and Collective Soul. It&#8217;s not riding genre trends. It&#8217;s playing from the gut—and it shows.
It&#8217;s 2025 is just getting started.
Lead image courtesy of Psyop

Cannabis

Entertainment

Media

Snoop Dogg's 'Last Dance' Is Cannabis Cinema At Its Weirdest—And There's A Funkadelic 'Dad Rock' Counterpart

SCCO

TECK

VALE

Shares of metals and materials stocks are trading higher following US Treasury Secretary Scott Bessent's reported remarks about trade de-escalation with China. De-escalation with China could reduce demand uncertainty.

Shares of Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) are soaring Tuesday after the company announced it held senior-level briefings with White House officials and the U.S. Food and Drug Administration (FDA), which resulted in strong interest in potential military and defense <a href="https://www.benzinga.com/pressreleases/25/04/b44920336/tivic-health-reports-white-house-briefing-and-fda-meetings-secured-positive-interest-in-potential-">product candidates</a>.
What To Know: Tivic disclosed that it presented its therapeutic programs to senior leadership at the White House and FDA on Thursday. Discussions centered around the company's TLR5 and non-invasive cervical vagus nerve stimulation (ncVNS) programs. 
The White House meeting focused on the TLR5 program and its lead product candidate, Entolimod, which is being developed to treat acute radiation syndrome. The briefing addressed the need for better treatment options for radiation exposure and highlighted Entolimod's role in enhancing immune response through the TLR5 pathway, which is part of the body's innate immune system.
The company noted that Entolimod previously received significant development funding from various U.S. government agencies, including BARDA, NASA, the Defense Threat Reduction Agency, the Department of the Army and the Department of Defense. Tivic emphasized the potential for Entolimod to offer advantages over current treatments, such as providing gastrointestinal and hematopoietic protection from radiation in a single dose.
In a separate meeting, Tivic met with senior leadership at the FDA to discuss potential expedited regulatory pathways for both Entolimod and Entolasta, a second-generation TLR5 agonist. 
The company also presented its ncVNS program to the FDA, which is targeting a range of inflammatory, cardiac and neurologic conditions. The FDA gave favorable feedback, including potential support for breakthrough device designation upon completion of relevant clinical work.
&#8220;We deeply appreciated the opportunity to discuss the importance of our clinical pipeline in potentially protecting and healing both active and retired military personnel, first responders, as well as U.S. citizens and our allies,&#8221; said Jennifer Ernst, CEO of Tivic Health.
&#8220;While these meetings were informal in nature, we expect to continue these discussions as Entolimod and our ncVNS medical programs progress toward potential FDA approval.&#8221;
TIVC Price Action: Tivic Health shares traded as high as $13.23 on Tuesday. The stock was up 107.7% at $7.28 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="543" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06-1024x543.png" alt="" class="wp-image-882548" style="width:476px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06-1024x543.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22134226/Screenshot-2025-04-22-at-13.42.06.png 1496w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44930495/wall-street-rebounds-ahead-of-tesla-earnings-dow-adds-1000-points-bitcoin-hits-91000-whats-driving-markets-tuesday">Wall Street Rebounds Ahead Of Tesla Earnings, Dow Adds 1,000 Points, Bitcoin Hits $91,000: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Image via Shutterstock.

TIVC

Tivic Health Systems Stock Is On Fire Today: What's Going On?

Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), considered a proxy for large-cap growth and tech-dense innovation, faltered considerably in 2025.
What Happened: The ETF has had year-to-date losses of 13.44%. While alarming on its own, this number conceals more profound undercurrents within its<a href="https://www.benzinga.com/etfs"> underlying makeup</a>, most notably the fortunes of &#8220;Magnificent Seven&#8221; stocks, which collectively comprise more than 40% of the QQQ.
The decline among these mega-cap growth stars has been swift and, by some accounts, historic. Roundhill Magnificent Seven ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>) mirrors this group of stocks and is down over 12% for the past six months.
As investment advisory company Bespoke Investment Group recently<a href="https://www.benzinga.com/25/04/44916598/tariff-pause-fizzles-mag-7-stocks-slide-back-to-pre-pause-lows"> noted, there is more downside risk</a>.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44895562/3-high-risk-etfs-aggressive-retail-investors-cant-stop-buying">3 High-Risk ETFs Aggressive Retail Investors Can&#8217;t Stop Buying</a>
A convergence of global macroeconomic headwinds has helped to bring about this weakness. J.P. Morgan Asset Management <a href="https://www.advisorpedia.com/markets/can-mega-cap-tech-stocks-withstand-the-tariff-pressure/">underscores </a>that around 75% of the suppliers to these companies are overseas, many in jurisdictions that are newly subject to fresh tariffs under new U.S. trade policy. 
Adding to the squeeze, corporate behemoths and Mag7 members such as Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) get more than half of their revenues abroad. Consequently, rising trade tensions and supply chain risks continue to be primary risk considerations for investors assessing exposure to QQQ or its underlying tech giants.
Why It Matters: A wider view presents a more complex picture. According <a href="https://www.advisorpedia.com/markets/can-mega-cap-tech-stocks-withstand-the-tariff-pressure/">to </a>J.P. Morgan&#8217;s Stephanie Aliaga, the recent decline has not been caused by a deterioration in underlying fundamentals. 
Instead, it is a repricing of risk in the face of heightened uncertainty regarding margins, capital spending, and earnings expectations. This has resulted in significant compression in valuation. 
Importantly, the forward price-to-earnings (P/E) multiple for the Magnificent Seven has fallen from around 31x early in the year to about 22x—its lowest price since January 2023, before the then-ongoing artificial intelligence (AI) cycle of investment.
This relative discount may attract long-term investors looking for quality at a better entry point. These companies are at the core of the QQQ portfolio and leading in innovation, especially in AI and cloud computing. Their impact on the overall market, and the QQQ, is still unbroken.
However, near-term prudence is likely to be justified. Trade headwinds are not likely to subside quickly, and more volatility in mega-cap growth can be expected. But for those with the stomach for short-term dislocations, the combination of cheap valuations and continued innovation leadership presents an attractive argument for revisiting QQQ and its Mag 7 exposure.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/04/44933272/rnty-yieldmaxs-bold-new-real-estate-etf-that-builds-income-one-option-at-a-time">RNTY: YieldMax&#8217;s Bold New Real Estate ETF That Builds Income, One Option At A Time</a></li>
</ul>
Image: Shutterstock

Specialty ETFs

ETFs

AAPL

GOOGL

MAGS

MSFT

Magnificent Meltdown: QQQ Tanks As Big Tech's Shine Wears Off, But There's A Silver Lining

AIRT

ARRY

AZEK

CARR

Embraer-Empresa Brasileira De Aeronautica

EVTL

HAYW

HLGN

JBHT

LDOS

MATX

NRGV

ODFL

PCAR

SAIA

SHLS

TREX

UHAL

Shares of companies in the broader industrial sector are trading higher following US Treasury Secretary Scott Bessent's reported remarks about trade de-escalation with China.

CMCSA

Xfinity Mobile Reveals New Premium Unlimited Plan That Delivers Gigabit Speeds And Upgraded Features

Old Second Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSBC#NASDAQ">OSBC</a>) will release its quarterly earnings report on Wednesday, 2025-04-23. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Old Second Bancorp to report an earnings per share (EPS) of $0.44.
Anticipation surrounds Old Second Bancorp's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.04, leading to a 2.41% drop in the share price on the subsequent day.
Here's a look at Old Second Bancorp's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.48</td>
<td>0.47</td>
<td>0.47</td>
<td>0.46</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.44</td>
<td>0.51</td>
<td>0.46</td>
<td>0.47</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>6.0%</td>
<td>-2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745348609_0.png" alt="eps graph" />
<h3>Old Second Bancorp Share Price Analysis</h3>
Shares of Old Second Bancorp were trading at $14.68 as of April 21. Over the last 52-week period, shares are up 4.66%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/OSBC/earnings">To track all earnings releases for Old Second Bancorp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

OSBC

An Overview of Old Second Bancorp's Earnings

Kaiser Aluminum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALU#NASDAQ">KALU</a>) will release its quarterly earnings report on Wednesday, 2025-04-23. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Kaiser Aluminum to report an earnings per share (EPS) of $0.41.
Anticipation surrounds Kaiser Aluminum's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.08, which was followed by a 4.88% increase in the share price the next day.
Here's a look at Kaiser Aluminum's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.41</td>
<td>0.83</td>
<td>0.91</td>
<td>0.57</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.33</td>
<td>0.51</td>
<td>0.65</td>
<td>1.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>-0.0%</td>
<td>-16.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745348597_0.png" alt="eps graph" />
<h3>Tracking Kaiser Aluminum's Stock Performance</h3>
Shares of Kaiser Aluminum were trading at $53.65 as of April 21. Over the last 52-week period, shares are down 36.02%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Views on Kaiser Aluminum</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Kaiser Aluminum.
The consensus rating for Kaiser Aluminum is Buy, based on 1 analyst ratings. With an average one-year price target of $74.0, there's a potential 37.93% upside.
<h3>Analyzing Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Ivanhoe Electric, Nexa Res and Ryerson Holding, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Ivanhoe Electric, with an average 1-year price target of $13.0, suggesting a potential 75.77% downside.</li>
<li>Analysts currently favor an Underperform trajectory for Nexa Res, with an average 1-year price target of $5.33, suggesting a potential 90.07% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Ryerson Holding, with an average 1-year price target of $25.0, suggesting a potential 53.4% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for Ivanhoe Electric, Nexa Res and Ryerson Holding, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaiser Aluminum</td>
<td>Buy</td>
<td>6.06%</td>
<td>$79.50M</td>
<td>1.06%</td>
</tr>
<tr>
<td>Ivanhoe Electric</td>
<td>Outperform</td>
<td>-20.29%</td>
<td>$862K</td>
<td>6.52%</td>
</tr>
<tr>
<td>Nexa Res</td>
<td>Underperform</td>
<td>17.63%</td>
<td>$143.30M</td>
<td>-10.87%</td>
</tr>
<tr>
<td>Ryerson Holding</td>
<td>Neutral</td>
<td>-9.44%</td>
<td>$191.10M</td>
<td>-0.52%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Kaiser Aluminum ranks highest in Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
<h3>Get to Know Kaiser Aluminum Better</h3>
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
<h3>Understanding the Numbers: Kaiser Aluminum's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Kaiser Aluminum showcased positive performance, achieving a revenue growth rate of 6.06% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Kaiser Aluminum's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 0.93%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Kaiser Aluminum's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.06% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Kaiser Aluminum's ROA stands out, surpassing industry averages. With an impressive ROA of 0.31%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Kaiser Aluminum's debt-to-equity ratio stands notably higher than the industry average, reaching 1.61. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<a href="https://www.benzinga.com/quote/KALU/earnings">To track all earnings releases for Kaiser Aluminum visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KALU

Preview: Kaiser Aluminum's Earnings

SEI Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>) will release its quarterly earnings report on Wednesday, 2025-04-23. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate SEI Inv to report an earnings per share (EPS) of $1.14.
SEI Inv bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.00 in the last quarter, leading to a 3.7% increase in the share price on the following day.
Here's a look at SEI Inv's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.19</td>
<td>1.07</td>
<td>1.04</td>
<td>0.98</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.19</td>
<td>1.19</td>
<td>1.05</td>
<td>0.99</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>5.0%</td>
<td>-0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745348588_0.png" alt="eps graph" />
<h3>Market Performance of SEI Inv's Stock</h3>
Shares of SEI Inv were trading at $69.67 as of April 21. Over the last 52-week period, shares are up 8.12%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on SEI Inv</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on SEI Inv.
The consensus rating for SEI Inv is Neutral, based on 5 analyst ratings. With an average one-year price target of $84.2, there's a potential 20.86% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Franklin Resources, Blue Owl Capital and Hamilton Lane, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Franklin Resources, with an average 1-year price target of $19.62, suggesting a potential 71.84% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Blue Owl Capital, with an average 1-year price target of $25.6, suggesting a potential 63.26% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Hamilton Lane, with an average 1-year price target of $158.6, suggesting a potential 127.64% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
In the peer analysis summary, key metrics for Franklin Resources, Blue Owl Capital and Hamilton Lane are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEI Inv</td>
<td>Neutral</td>
<td>14.92%</td>
<td>$297.69M</td>
<td>6.76%</td>
</tr>
<tr>
<td>Franklin Resources</td>
<td>Neutral</td>
<td>13.08%</td>
<td>$1.83B</td>
<td>1.19%</td>
</tr>
<tr>
<td>Blue Owl Capital</td>
<td>Outperform</td>
<td>27.80%</td>
<td>$336.88M</td>
<td>1.00%</td>
</tr>
<tr>
<td>Hamilton Lane</td>
<td>Neutral</td>
<td>34.33%</td>
<td>$128.63M</td>
<td>8.44%</td>
</tr>
</tbody>
</table>

Key Takeaway:
SEI Inv ranks in the middle for Consensus. It is at the bottom for Revenue Growth and Gross Profit, but at the top for Return on Equity among its peers.
<h3>Get to Know SEI Inv Better</h3>
SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $87 billion in assets under management. As of December 2024, SEI (including LSV) manages, administers, or advises about $1.6 trillion in assets.
<h3>SEI Inv: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, SEI Inv showcased positive performance, achieving a revenue growth rate of 14.92% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 27.96%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): SEI Inv's ROE excels beyond industry benchmarks, reaching 6.76%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): SEI Inv's ROA stands out, surpassing industry averages. With an impressive ROA of 5.8%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: SEI Inv's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/SEIC/earnings">To track all earnings releases for SEI Inv visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SEIC

Earnings Outlook For SEI Inv

Lithia Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) will release its quarterly earnings report on Wednesday, 2025-04-23. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Lithia Motors to report an earnings per share (EPS) of $7.75.
The market awaits Lithia Motors's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.55, leading to a 0.26% drop in the share price on the subsequent day.
Here's a look at Lithia Motors's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>7.24</td>
<td>7.59</td>
<td>7.54</td>
<td>7.89</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>7.79</td>
<td>8.21</td>
<td>7.87</td>
<td>6.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>0.0%</td>
<td>-2.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745348576_0.png" alt="eps graph" />
<h3>Tracking Lithia Motors's Stock Performance</h3>
Shares of Lithia Motors were trading at $283.82 as of April 21. Over the last 52-week period, shares are up 19.26%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Lithia Motors</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Lithia Motors.
The consensus rating for Lithia Motors is Outperform, based on 7 analyst ratings. With an average one-year price target of $383.0, there's a potential 34.94% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of AutoNation, CarMax and Group 1 Automotive, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for AutoNation, with an average 1-year price target of $194.75, suggesting a potential 31.38% downside.</li>
<li>Analysts currently favor an Outperform trajectory for CarMax, with an average 1-year price target of $90.3, suggesting a potential 68.18% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Group 1 Automotive, with an average 1-year price target of $454.0, suggesting a potential 59.96% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for AutoNation, CarMax and Group 1 Automotive, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lithia Motors</td>
<td>Outperform</td>
<td>19.54%</td>
<td>$1.37B</td>
<td>3.26%</td>
</tr>
<tr>
<td>AutoNation</td>
<td>Neutral</td>
<td>6.59%</td>
<td>$1.24B</td>
<td>7.71%</td>
</tr>
<tr>
<td>CarMax</td>
<td>Outperform</td>
<td>6.69%</td>
<td>$667.89M</td>
<td>1.44%</td>
</tr>
<tr>
<td>Group 1 Automotive</td>
<td>Outperform</td>
<td>23.80%</td>
<td>$879.20M</td>
<td>3.12%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Lithia Motors ranks at the top for Revenue Growth and Gross Profit among its peers. However, it has the lowest Return on Equity. Overall, Lithia Motors is positioned favorably compared to its peers in terms of financial performance metrics.
<h3>Delving into Lithia Motors's Background</h3>
Lithia Motors is a retailer of new and used vehicles and related services. The company offers over 50 brands of vehicles at nearly 500 stores globally across the US, Canada, and UK. The company has expanded largely through the acquisition of dealerships in smaller regional markets but now seeks to grow in any part of the US and we expect more deals over time in the US and, at times, abroad. Annual revenue in 2024 was $36.2 billion and we see over $50 billion possible in a few years. The US was 78% of 2024 revenue and the UK second at 19%, due to the 2024 Pendragon acquisition. In 2024, new vehicle sales were about 49% of total revenue. Lithia was founded in 1946, went public in 1996, and is the largest US auto dealer. It is based in Medford, Oregon.
<h3>Financial Milestones: Lithia Motors's Journey</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Lithia Motors showcased positive performance, achieving a revenue growth rate of 19.54% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Lithia Motors's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.36%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Lithia Motors's ROE excels beyond industry benchmarks, reaching 3.26%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Lithia Motors's ROA excels beyond industry benchmarks, reaching 0.93%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 2.08.
<a href="https://www.benzinga.com/quote/LAD/earnings">To track all earnings releases for Lithia Motors visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Lithia Motors's Earnings

Taylor Morrison Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMHC#NYSE">TMHC</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-23. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Taylor Morrison Home to report an earnings per share (EPS) of $1.81.
Investors in Taylor Morrison Home are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.26, which was followed by a 0.78% drop in the share price the next day.
Here's a look at Taylor Morrison Home's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.38</td>
<td>2.06</td>
<td>1.90</td>
<td>1.60</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.64</td>
<td>2.37</td>
<td>1.97</td>
<td>1.75</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>-0.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745348567_0.png" alt="eps graph" />
<h3>Taylor Morrison Home Share Price Analysis</h3>
Shares of Taylor Morrison Home were trading at $55.59 as of April 21. Over the last 52-week period, shares are up 3.92%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on Taylor Morrison Home</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Taylor Morrison Home.
Analysts have provided Taylor Morrison Home with 4 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $70.25, suggesting a potential 26.37% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Meritage Homes, Champion Homes and Installed Building Prods, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Meritage Homes, with an average 1-year price target of $80.0, suggesting a potential 43.91% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Champion Homes, with an average 1-year price target of $99.67, suggesting a potential 79.29% upside.</li>
<li>Analysts currently favor an Buy trajectory for Installed Building Prods, with an average 1-year price target of $207.5, suggesting a potential 273.27% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
Within the peer analysis summary, vital metrics for Meritage Homes, Champion Homes and Installed Building Prods are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taylor Morrison Home</td>
<td>Outperform</td>
<td>16.67%</td>
<td>$564.01M</td>
<td>4.19%</td>
</tr>
<tr>
<td>Meritage Homes</td>
<td>Neutral</td>
<td>-2.31%</td>
<td>$380.31M</td>
<td>3.39%</td>
</tr>
<tr>
<td>Champion Homes</td>
<td>Neutral</td>
<td>15.28%</td>
<td>$181.02M</td>
<td>4.07%</td>
</tr>
<tr>
<td>Installed Building Prods</td>
<td>Buy</td>
<td>4.09%</td>
<td>$251.80M</td>
<td>9.41%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Taylor Morrison Home ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Consensus rating and Return on Equity.
<h3>All You Need to Know About Taylor Morrison Home</h3>
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.
<h3>Unraveling the Financial Story of Taylor Morrison Home</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Taylor Morrison Home displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 16.67%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.29%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Taylor Morrison Home's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.19%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.61%, the company showcases effective utilization of assets.
Debt Management: Taylor Morrison Home's debt-to-equity ratio is below the industry average. With a ratio of 0.37, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/TMHC/earnings">To track all earnings releases for Taylor Morrison Home visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TMHC

Taylor Morrison Home Earnings Preview

Financial giants have made a conspicuous bullish move on T-Mobile US. Our analysis of options history for T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) revealed 10 unusual trades.
Delving into the details, we found 30% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $208,469, and 5 were calls, valued at $191,586.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $230.0 to $310.0 for T-Mobile US during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for T-Mobile US's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of T-Mobile US's whale trades within a strike price range from $230.0 to $310.0 in the last 30 days. 
<h3>T-Mobile US Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745348565_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMUS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/25/25</td>
<td>$6.7</td>
<td>$6.05</td>
<td>$6.7</td>
<td>$257.50</td>
<td>$53.6K</td>
<td>25</td>
<td align="right">178</td>
</tr>
<tr>
<td>TMUS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/25/25</td>
<td>$7.0</td>
<td>$5.75</td>
<td>$6.4</td>
<td>$257.50</td>
<td>$51.2K</td>
<td>25</td>
<td align="right">83</td>
</tr>
<tr>
<td>TMUS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$6.15</td>
<td>$5.9</td>
<td>$6.14</td>
<td>$250.00</td>
<td>$47.9K</td>
<td>2.2K</td>
<td align="right">80</td>
</tr>
<tr>
<td>TMUS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/25/25</td>
<td>$4.45</td>
<td>$4.1</td>
<td>$4.42</td>
<td>$252.50</td>
<td>$46.6K</td>
<td>34</td>
<td align="right">272</td>
</tr>
<tr>
<td>TMUS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/25/25</td>
<td>$4.45</td>
<td>$4.15</td>
<td>$4.33</td>
<td>$252.50</td>
<td>$41.0K</td>
<td>34</td>
<td align="right">517</td>
</tr>
</tbody>
</table>

<h3>About T-Mobile US</h3>
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, and that firm merged with Sprint in 2020, creating the second-largest wireless carrier in the us. T-Mobile now serves 77 million postpaid and 21 million prepaid phone customers, equal to around 30% of the us retail wireless market. The firm entered the fixed-wireless broadband market aggressively in 2021 and now serves more than 5 million residential and business customers. In addition, T-Mobile provides wholesale services to resellers.
Having examined the options trading patterns of T-Mobile US, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of T-Mobile US</h3>
<ul>
<li>Trading volume stands at 2,764,506, with TMUS's price up by 1.31%, positioned at $256.81.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 2 days.</li>
</ul>
<h3>What Analysts Are Saying About T-Mobile US</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $275.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Benchmark downgraded its rating to Buy, setting a price target of $275. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for T-Mobile US with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

TMUS

Smart Money Is Betting Big In TMUS Options

Deep-pocketed investors have adopted a bullish approach towards Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PLTR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 97 extraordinary options activities for Palantir Technologies. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 53% leaning bullish and 37% bearish. Among these notable options, 37 are puts, totaling $3,046,402, and 60 are calls, amounting to $3,884,242.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $155.0 for Palantir Technologies over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Palantir Technologies's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Palantir Technologies's significant trades, within a strike price range of $30.0 to $155.0, over the past month.
<h3>Palantir Technologies Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745348560_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/23/25</td>
<td>$0.97</td>
<td>$0.89</td>
<td>$0.97</td>
<td>$60.00</td>
<td>$776.0K</td>
<td>20.7K</td>
<td>10.1K</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.45</td>
<td>$61.8</td>
<td>$62.2</td>
<td>$35.00</td>
<td>$186.6K</td>
<td>9.7K</td>
<td>50</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$2.96</td>
<td>$2.92</td>
<td>$2.92</td>
<td>$65.00</td>
<td>$139.9K</td>
<td>5.8K</td>
<td>495</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$4.9</td>
<td>$4.8</td>
<td>$4.8</td>
<td>$110.00</td>
<td>$139.2K</td>
<td>634</td>
<td>633</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$14.6</td>
<td>$14.5</td>
<td>$14.6</td>
<td>$97.50</td>
<td>$127.0K</td>
<td>1.1K</td>
<td>179</td>
</tr>
</tbody>
</table>

<h3>About Palantir Technologies</h3>
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.
In light of the recent options history for Palantir Technologies, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Palantir Technologies's Current Market Status</h3>
<ul>
<li>Trading volume stands at 73,511,636, with PLTR's price up by 3.98%, positioned at $94.41.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 13 days.</li>
</ul>
<h3>What Analysts Are Saying About Palantir Technologies</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $95.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Palantir Technologies, which currently sits at a price target of $90. 
&#x2A; Maintaining their stance, an analyst from DA Davidson continues to hold a Neutral rating for Palantir Technologies, targeting a price of $100. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Palantir Technologies with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

PLTR

Market Whales and Their Recent Bets on PLTR Options

Prosperity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PB#NYSE">PB</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-23. Here's what investors need to know before the announcement.
Analysts estimate that Prosperity Bancshares will report an earnings per share (EPS) of $1.35. 
Anticipation surrounds Prosperity Bancshares's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.04 in the last quarter, leading to a 1.08% increase in the share price on the following day.
Here's a look at Prosperity Bancshares's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.33</td>
<td>1.31</td>
<td>1.18</td>
<td>1.16</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.37</td>
<td>1.34</td>
<td>1.22</td>
<td>1.18</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>0.0%</td>
<td>2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745348558_0.png" alt="eps graph" />
<h3>Performance of Prosperity Bancshares Shares</h3>
Shares of Prosperity Bancshares were trading at $65.53 as of April 21. Over the last 52-week period, shares are up 3.19%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/PB/earnings">To track all earnings releases for Prosperity Bancshares visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Prosperity Bancshares's Earnings Preview

Press Releases

Lavras Gold Corp. Issues Stock Options & RSUs

Lavras Gold Ranked in the Top 10 of the "Venture Exchange 50" Mining Companies for the Second Year in a Row

LGCFF

TSXV:LGC

Lavras Gold

Comments

Lavras Gold

Actualités

Dernières nouvelles pour Lavras Gold (OTC:LGCFF) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL